Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.

James Chun Yip ChanPei Shi OngPeirong LimPreben Xiang Long TengEric Chun Yong Chan

Published in: Cancer chemotherapy and pharmacology (2016)

This forward-looking study extends the success of tamoxifen by exploring the effectiveness of combining the next-generation tamoxifen derivative, endoxifen with an anti-HER2 agent to combat ERα/HER2 crosstalk, and at the same time provides a solution to the predicted pharmacokinetic antagonism between lapatinib and tamoxifen.

Keyphrases

breast cancer cells
positive breast cancer
estrogen receptor
randomized controlled trial
systematic review
metastatic breast cancer
cancer therapy
water soluble